Thus, our work identified CD39-dependent phenotypes in CAR Tregs, and revealed that CD39+ Tregs may represent a better choice for therapeutic islet targeting strategies in T1D. The gene discussed is ENTPD1; the disease is type 1 diabetes mellitus.